×
About 60,965 results

ALLMedicine™ Hepatocellular Carcinoma Center

Research & Reviews  22,419 results

Aptamer-mediated doxorubicin delivery reduces HCC burden in 3D organoids model.
https://doi.org/10.1016/j.jconrel.2021.11.036
Journal of Controlled Release : Official Journal of the C... Zhou K, Huo X et. al.

Dec 2nd, 2021 - Epithelial cell adhesion molecule (EpCAM) is a surface marker which is frequently overexpressed in hepatocellular carcinoma (HCC) but minimally expressed on mature hepatocytes. We developed a specific aptamer against EpCAM (EpCAM-apt) and tested i...

Differences in Transport Characteristics and Cytotoxicity of Epirubicin and Doxorubicin...
https://doi.org/10.21873/anticanres.15430
Anticancer Research; Nagai K, Fukuno S et. al.

Dec 2nd, 2021 - Epirubicin (EPI), an epimer of doxorubicin (DOX), and DOX are anthracycline agents with broad-spectrum antitumor activity. The aim of the present study was to elucidate the transport characteristics of EPI and DOX in human hepatocellular carcinoma...

Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series.
https://doi.org/10.21873/anticanres.15442
Anticancer Research; Aoki H, Matsumoto N et. al.

Dec 2nd, 2021 - Hepatocellular carcinoma (HCC) occasionally presents with simultaneous or metachronous primary malignancies of other organs. Despite the limited scope of cytocidal anticancer drugs or molecular targeted agents, immune checkpoint inhibitors (ICIs) ...

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HC...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615147
Journal of Hepatocellular Carcinoma; De Battista D, Zamboni F et. al.

Dec 2nd, 2021 - HCC is the third leading cause of cancer-related death worldwide, with chronic viral hepatitis accounting for more than 70% of the cases. Therapeutic options are limited and ineffective. The increasing use of immune-based therapies in solid tumors...

The microbial metabolome in metabolic-associated fatty liver disease.
https://doi.org/10.1111/jgh.15746
Journal of Gastroenterology and Hepatology; Li M, Rajani C et. al.

Dec 2nd, 2021 - Metabolism-associated fatty liver disease (MAFLD) is defined as the presence of excess fat in the liver in the absence of excess alcohol consumption and metabolic dysfunction. It has also been described as the hepatic manifestation of metabolic sy...

see more →

Guidelines  29 results

Non-invasive diagnosis and follow-up in liver transplantation.
https://doi.org/10.1016/j.clinre.2021.101774
Clinics and Research in Hepatology and Gastroenterology; Dumortier J, Besch C et. al.

Aug 1st, 2021 - The field of liver transplantation directly or indirectly embodies all liver diseases, in addition to specific ones related to organ rejection (cellular and humoral). The recommended non-invasive methods for determining the indication for liver tr...

Non-invasive diagnosis and follow-up of primary malignant liver tumours.
https://doi.org/10.1016/j.clinre.2021.101766
Clinics and Research in Hepatology and Gastroenterology; Nahon P, Aubé C et. al.

Aug 1st, 2021 - Among a wide range of malignant liver tumours, hepatocellular carcinoma (HCC) developed on a background of cirrhosis represents the most frequent clinical situation. In this setting, HCC is one of the rare solid tumours for which histological conf...

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0022
Journal of the National Comprehensive Cancer Network : JN... Benson AB, D'Angelica MI et. al.

May 25th, 2021 - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcino...

Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis,...
https://doi.org/10.1016/j.clinre.2020.101590
Clinics and Research in Hepatology and Gastroenterology; Blanc JF, Debaillon-Vesque A et. al.

Mar 30th, 2021 - This document is a summary of the French Intergroup guidelines regarding the management of hepatocellular carcinoma (HCC) published in March 2019. It is a collaborative work under the auspices of most of the French medical societies involved in th...

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achie...
https://doi.org/10.1053/j.gastro.2020.11.051
Gastroenterology Younossi ZM, Corey KE et. al.

Dec 12th, 2020 - Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with global public health impact affecting more than 25% of the global population. NAFLD is associated with significant morbidity and mortality from cirrhosis, h...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  726 results

The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
https://clinicaltrials.gov/ct2/show/NCT05121571

Nov 25th, 2021 - Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE. This study was to compare HAIC...

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
https://clinicaltrials.gov/ct2/show/NCT05135364

Nov 25th, 2021 - The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research. In this single-arm, open-label, prospective study, for those patients with unresectable primary HCC, in the case o...

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced ...
https://clinicaltrials.gov/ct2/show/NCT04605796

Nov 24th, 2021 - This is an open-label, single-arm, national multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with Bevacizumab as the first-line therapy for advanced HCC The study will use sa...

Clinical Application of Fibroblast Activation Protein PET/MRI in Liver Fibrosis
https://clinicaltrials.gov/ct2/show/NCT04605939

Nov 24th, 2021 - Liver fibrosis is a key step in the development of various chronic liver diseases (viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, autoimmune liver disease, etc.) to cirrhosis and an important link that affects the pro...

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04965454

Nov 24th, 2021 - This is a prospective open-label single-arm diagnostic clinical trial evaluating fluorine-18 fluorocholine (FCH) PET/CT and cell-free DNA mutation profiling (also referred to as genomic liquid biopsy) as diagnostic tools for predicting therapeutic...

see more →

News  1,193 results

Clinical Edge Journal Scan Commentary: HCC December 2021
https://www.mdedge.com/fedprac/article/249086/hepatocellular-carcinoma/clinical-edge-journal-scan-commentary-hcc-december
Nevena Damjanov, MD

Nov 23rd, 2021 - Nevena Damjanov, MD Hepatocellular carcinoma (HCC) benefits from multidisciplinary care. This month we will review articles that address different approaches to the treatment for HCC, their outcomes, and potential complications.

Liver Cancer Risk Lingers Even After HCV Eradication
https://www.medscape.com/viewarticle/963101

Nov 17th, 2021 - Although the risk for liver cancer diminishes for patients with hepatitis C virus (HCV) infections for whom virus is eliminated with direct-acting antiviral (DAA) drugs, these patients are not out of the woods, and those who do not have a sustaine...

Skyrocketing Demand for Liver Transplant Among Older Americans
https://www.medscape.com/viewarticle/962947

Nov 16th, 2021 - NEW YORK (Reuters Health) - Over the past two decades, the need for liver transplant (LT) in older adults has risen sharply, due to rising rates of nonalcoholic steatohepatitis (NASH), and the outcomes of LT in these patients has been improving, a...

Reduction hepatectomy plus multidisciplinary therapy improves HCC outcomes
https://www.mdedge.com/fedprac/article/248709/hepatocellular-carcinoma/reduction-hepatectomy-plus-multidisciplinary-therapy

Nov 15th, 2021 - Key clinical point: Hepatocellular carcinoma patients who achieved complete remission with postoperative treatment after reduction hepatectomy fared better than those who achieved remission without postoperative treatment. Major finding: The 5-yea.

AGA Clinical Care Pathway: Screening, diagnosis, and treatment of NAFLD and NASH
https://www.mdedge.com/internalmedicine/article/248632/gastroenterology/aga-clinical-care-pathway-screening-diagnosis-and
Will Pass

Nov 12th, 2021 - The American Gastroenterological Association recently published a Clinical Care Pathway for screening, diagnosis, and treatment of patients with nonalcoholic fatty liver disease (NAFLD). Recommendations are intended for a spectrum of clinical sett.

see more →

Patient Education  4 results see all →